Advantage Alpha Capital Partners LP Makes New Investment in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Advantage Alpha Capital Partners LP acquired a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 5,772 shares of the specialty pharmaceutical company’s stock, valued at approximately $344,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in ANI Pharmaceuticals by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 1,306,432 shares of the specialty pharmaceutical company’s stock valued at $90,314,000 after purchasing an additional 17,460 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of ANI Pharmaceuticals by 3.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 630,226 shares of the specialty pharmaceutical company’s stock valued at $40,132,000 after acquiring an additional 21,053 shares during the period. Pacer Advisors Inc. raised its stake in ANI Pharmaceuticals by 23,259.8% in the 3rd quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company’s stock worth $33,907,000 after acquiring an additional 565,910 shares during the last quarter. Global Alpha Capital Management Ltd. lifted its position in ANI Pharmaceuticals by 1.8% during the 3rd quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company’s stock worth $32,005,000 after acquiring an additional 9,500 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in ANI Pharmaceuticals by 3.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 250,346 shares of the specialty pharmaceutical company’s stock valued at $14,936,000 after purchasing an additional 8,869 shares during the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ANIP. HC Wainwright reaffirmed a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, November 11th. StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Piper Sandler began coverage on shares of ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an “overweight” rating and a $68.00 price objective on the stock. Raymond James boosted their target price on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research report on Wednesday, September 18th. Finally, Truist Financial upped their price target on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a report on Tuesday, October 22nd. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.33.

ANI Pharmaceuticals Stock Down 1.3 %

ANIP stock opened at $57.86 on Wednesday. ANI Pharmaceuticals, Inc. has a one year low of $48.20 and a one year high of $70.81. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The firm’s fifty day moving average is $58.36 and its 200 day moving average is $60.83. The firm has a market cap of $1.22 billion, a PE ratio of -105.20 and a beta of 0.71.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The business had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. The company’s revenue for the quarter was up 12.5% on a year-over-year basis. During the same period in the prior year, the company posted $1.05 EPS. On average, research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.